Short Interest In DepoMed Moves 11% Lower

The most recent short interest data has been released by the NASDAQ for the 04/15/2013 settlement date, which shows a 345,760 share decrease in total short interest for DepoMed, Inc. ( DEPO), to 2,796,172, a decrease of 11.00% since 03/28/2013. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days (at the average volume) it would take to close out all of the open short positions if every share traded represented a short position being closed. Average daily volume for DEPO at the 04/15/2013 settlement increased to 493,457, as compared to 371,326 at the 03/28/2013 report. That brought "days to cover" down to 5.67, a 33.03% decrease from the 8.46 days to cover calculated at the previous short interest data release. The below chart shows the historical "days to cover" for DEPO at previous short interest release dates:

A decreased "days to cover" value could indicate that short sellers are no longer expecting the same decline in stock price they once were, or it could also indicate a long bet elsewhere was closed where DEPO had been shorted as a hedge.

The 10 Most Shorted Stocks of the Dow »

The chart below shows the one year performance of DEPO shares, versus its 200 day moving average. Looking at this chart, DEPO's low point in its 52 week range is $4.75 per share, with $7.15 as the 52 week high point — that compares with a last trade of $5.48.

If you liked this article you might like

Opioid Makers Buffeted by Trump's Declaration of Addiction Crisis

Biotech Movers: FibroGen Leaps on Results for Pulmonary Fibrosis Study

Depomed, Insys Shares Down After FDA Decision on Endo's Opana ER

Young Guns of Activism Join Boards at AIG, SunOpta and DepoMed

Depomed Focuses on Flagship Drug Rather Than M&A: CEO